Loading...
Loading...
Contributors:
Dataset URI:
10.1371/journal.pone.0140351.t001↓: diminished↑: increased; p53-AAbs: p53 autoantibodies; y: years; m: months; FIGO: International Federation of Gynecology and Obstetrics; NOS: Newcastle-Ottawa Quality Assessment Scale; perc.: percentile; Uni: univariate; Multi: multivariate; NA: Not Available; TRI: Time-resolved immunofluorimetric assay; S: Serous; U: Undifferentiated; M: Mucinous; C: Clear cell; E: Endometroid; Mx: Mixed; P: Papillary; O: Other; G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated; G4: undifferentiated;Rx: Residual tumour size indefinite1NOS score (range, 1–9) was assigned only to the included studies253/130 patients enrolled prior to first surgery3all these patients (N = 43) had III-IV FIGO stage446/99 patients enrolled prior to first surgery5Follow-up data available for patients dead and alive6data available only for patients with serous tumour histotype.Summary of clinical-pathological characteristics of studies reporting associations between +p53-AAbs and survival in ovarian cancer.
Keyword(s):
baseline tumour characteristics; ci; dfs; heterogeneity.ConclusionsThe prognostic significance; multivariate HR.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)